Skip to content

A clinical study to compare the efficacy of add-on Ayurveda treatment versus Allopathy treatment in Mood disorders

Integrative Ayurveda and Yoga therapeutic regimen as on Add-on to conventional management of Mood Disorder: An RCT for evaluation of safety and assessment of Clinical, functional Neuroimaging, Gut biomarkers, autonomic functions, Genomics and Cognitive function parameters

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/077656
Enrollment
60
Registered
2024-12-04
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F30-F39- Mood [affective] disorders

Interventions

None listed

Sponsors

Ministry of AYUSH, Government of India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients more than 18 years of age. 2. Diagnosed of unipolar/bipolar depression as per screening Mini International Neuropsychiatric Interview (MINI). 3. Patients suitable for Virechana. 4. Ready to sign the informed consent form. 5. Right-handed subjects tested with Edinburgh Handedness Questionnaire. 6. At least 8 years of formal education.

Exclusion criteria

Exclusion criteria: 1. Patients on nutraceutical mood remedies - Such as St. Johnâ??s Wort, fish oil, SAMe, or high-dose vitamins - within 2 months of screening, or plan to initiate use during study. 2. Patients on psychotherapy or plan to initiate during study. 3. Patients who are already on yoga/mind-body practices or plan to initiate such practices during the study. 4. Patients whose impaired cognition score 5. Patients diagnosed with substance use disorder within 3 months of screening MINI. 6. Patients diagnosed with bipolar disorder or other Axis I disorder comorbid with major depression per screening MINI. 7. Patients with major depression, score > 28 on screening BDI. 8. Patients with history of suicide attempts, suicidal ideation or psychosis. 9. Any neurological disorders such as any significant head injury. 10. Patients with neuro degenerative disorders. 11. Patients of substance use disorders. 12. Pregnant and lactating women. 13. Patients with uncontrolled Type 2 Diabetes mellitus 14. Patients on β-blockers, thiazide diuretics, corticosteroids, HRT. 15. Patients with Uncontrolled Blood pressure. 16. Patients with concurrent Hepatic Dysfunction 17. Patients with Renal Dysfunction Patients with severe Pulmonary Dysfunction 18. Patients with evidence of malignancy 19. Patients suffering from major systemic illness necessitating long-term drug treatment. 20. Patients who have completed participation in any other clinical trial during the past six (06) months. 21. Left-handedness 22. Education level is less than 8th grade.

Design outcomes

Primary

MeasureTime frame
Changes in Hamilton Depression Rating Scale (HDRS), MADRAS, and Vishadha rating scaleTimepoint: Baseline, after virechana, 45th and 90th day

Secondary

MeasureTime frame
1. Changes in functional Magnetic Resonance Imaging (fMRI) 2. Changes in Herat Rate Variability (HRV). 3. Changes in Neuro gut biomarkers 4. Changes in Telomere length Timepoint: Baseline, after virechana, 45th and 90th day

Countries

India

Contacts

Public ContactDr Kishore Kumar R

National Institute of Mental Health and Neurosciences

ayurkishore@yahoo.com09845829174

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026